Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis

Inclusion Criteria: * Individuals age 18-70 years old with eyelid dermatitis for at least two months * Failure of at least one topical prescription cream for the eyelid dermatitis (steroid, pimecrolimus, tacrolimus, crisaborole, or ruxolitinib) * Women of reproductive potential must agree to using effective contraception during treatment and for 4 weeks following the final dose of Upadacitinib. * Willing and able participants that provide informed consent * Willing and able participants that comply with study activities Exclusion Criteria: * Self-reported history of allergic response to upadacitinib * Subject with self-reported history of heart disease, stroke, or neurological conditions * Currently taking topical medications for eyelid dermatitis within one week of starting study drug * Women who are pregnant, nursing, or who may become pregnant during the study * Non-English-speaking subjects * Patients with an active serious infection * Patients with active TB or latent TB, patients should be tested for TB prior to upadacitinib treatment. * Patients with active HBV/HCV or abnormal lab ranges, Lab Data: Hb\<8g/dL, ALC\<500 cells/mm3 and ANC \<1000 cells/mm3 * Patients with a history of malignancy within the last 5 years other than successfully treated NMSC.